Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09 November 2, 2020
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering October 28, 2020
Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09 October 28, 2020
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering September 24, 2020
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation September 18, 2020
Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare September 15, 2020
Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation September 14, 2020
